Ed Barker to Melphalan
This is a "connection" page, showing publications Ed Barker has written about Melphalan.
Connection Strength
0.290
-
Lysis of antigenically unrelated tumor cells mediated by Lyt 2+ splenic T-cells from melphalan-cured MOPC-315 tumor bearers. Cancer Res. 1989 Sep 15; 49(18):5007-15.
Score: 0.087
-
Importance of Lyt-2+ T-cells in the resistance of melphalan-cured MOPC-315 tumor bearers to a challenge with MOPC-315 tumor cells. Cancer Res. 1988 Sep 01; 48(17):4834-42.
Score: 0.081
-
Some characteristics of the in vivo antitumor immunity exhibited by mice cured of a large MOPC-315 tumor by a low dose of melphalan. Cancer Immunol Immunother. 1987; 25(3):215-24.
Score: 0.072
-
Phorbol ester-induced enhancement in lytic activity of CD8+ splenic T cells from low-dose melphalan-treated MOPC-315-tumor bearers. Cancer Immunol Immunother. 1991; 32(6):353-63.
Score: 0.024
-
Importance of Lyt 2+ T-cells in the curative effectiveness of a low dose of melphalan for mice bearing a large MOPC-315 tumor. Cancer Res. 1989 Aug 15; 49(16):4597-606.
Score: 0.022
-
Eradication of a large MOPC-315 tumor in athymic nude mice by chemoimmunotherapy with Lyt2+ splenic T cells from melphalan-treated BALB/c mice bearing a large MOPC-315 tumor. Cancer Immunol Immunother. 1990; 31(3):129-38.
Score: 0.006